Obesity-related hypertension: Its physiological basis and pharmacological approaches to its treatment

Journal of Human Hypertension

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Richards, R J ^a   Thakur, V ^a   Reisin, E ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Obesity; Physiology; Therapy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPOPROTEIN;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DROWSINESS; DYSLIPIDEMIA; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN SENSITIVITY; OBESITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; OBESITY; WEIGHT LOSS;

EID: 0029744862     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Stamler R et al. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607-1610.
2. Hsu PH, Mathewson FA, Rabkin SW. Blood pressure and body mass index patterns - a longitudinal study. J Chronic Dis 1977; 30: 93-113.
3. Reisin E et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1-6.
4. Seidell JC et al. Fat distribution of overweight persons in relation to morbidity and subjective health. Int J Obes 1985; 9: 363-374.
5. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72: 1150-1162.
6. +-ATP-ase, and obesity. (Letter) Lancet 1981; 1: 836.
7. Baumgart P et al. Obesity, hypertension and intracellular electrolytes. Klin Wochenschr 1983; 61: 803-805.
8. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
9. Zemel MB. Insulin resistance, obesity and hypertension: an overview. J Nutr 1995; 125 (Suppl 6): S1715-S1717.
10. Hall JE, Brands MW, Zappe DH, Alonso-Galicia M. Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med 1995; 208: 317-329.
11. Landsberg L. Insulin and hypertension: introduction. Proc Soc Exp Biol Med 1995; 208: 315-316.
12. Zimlichman R et al. Insulin induces medial hypertrophy of myocardial arterioles in rats. Am J Hypertens 1995; 8: 915-920.
13. DeFronzo RA et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-855.
14. Feldman RD, Hramiak IM, Finegood DT, Behme MT. Parallel regulation of the local vascular and systemic metabolic effects of insulin. J Clin Endocrinol Metab 1995; 80: 1556-1559.
15. Rocchini AP et al. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57: 613-618.
16. Hiramatsu K et al. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981; 29: 25-30.
17. Messerli FH et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141: 81-85.
18. Tuck ML et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
19. Young JB, Landsberg L. Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. J Chronic Dis 1982; 35: 879-886.
20. Sims EA. Mechanisms of hypertension in the overweight. Hypertension 1982; 4: III43-49.
21. Reisin E. Obesity hypertension: nonpharmacologic and pharmacologic therapeutic modalities. In: Laragh JH and Brenner BM (eds). Hypertension: pathophysiology, diagnosis, and management. Second edition. Raven Press Ltd: New York, 1995, pp 2683-2691.
22. Messerli FH et al. Disparate cardiovascular effects of obesity and essential hypertension. Am J Med 1983; 74: 808-812.
23. Brands MW et al. Obesity and hypertension: roles of hyperinsulinemia, sympathetic nervous system and intrarenal mechanisms. J Nutr 1995; 125 (Suppl 6): S1725-S1731.
24. Langford HG et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985; 253: 657-664.
25. Reisin E, Frohlich ED. Effects of weight reduction on arterial pressure. J Chronic Dis 1982; 35: 887-891.
26. Reisin E et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 1983; 98: 315-319.
27. Genuth SM. Insulin secretion in obesity and diabetes: an illustrative case. Ann Intern Med 1977; 87: 714- 716.
28. Grey N, Kipnis DM. Effect of diet composition on the hyperinsulinemia of obesity. N Engl J Med 1971; 285: 827-831.
29. Eggena P et al. Hormonal correlates of weight loss associated with blood pressure reduction. Clin Exp Hypertens 1991; 13: 1447-1456.
30. Shetty PS, Jung RT, James WP. Effect of catecholamine replacement with levodopa on the metabolic response to semistarvation. Lancet 1979; 1: 77-79.
31. Weder AB, Torretti BA, Katch VL, Rocchini AP. The antihypertensive effect of calorie restriction in obese adolescents: dissociation of effects on erythrocyte countertransport and cotransport. J Hypertens 1984; 2: 507-514.
32. Scherrer U et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation 1991; 83: 552-558.
33. Alexander JK, Peterson KL. Cardiovascular effects of weight reduction. Circulation 1972; 45: 310-318.
34. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-339.
35. Toto-Moukouo JJ et al. Pulse wave velocity in patients with obesity and hypertension. Am Heart J 1986; 112: 136-140.
36. Wilson IM, Preis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 1959; 20: 1028-1036.
37. The Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
38. Frohlich ED, Schnaper HW, Wilson IM, Preis ED. Hemodynamic alterations in hypertensive patients due to chlorothiazide. N Engl J Med 1960; 262: 1261-1263.
39. Reisin E, Weed SG. The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. J Hypertens 1992; 10: 489-493.
40. Modan M et al. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991; 17: 565-573.
41. Johnson BF et al. The effects of thiazide diuretics upon plasma lipoproteins. J Hypertension 1986; 4: 235-239.
42. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
43. MacMahon SW et al. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985; 1: 1233-1236.
44. Fagerberg B et al. Cardiovascular effects of weight reduction vs antihypertensive drug treatment: a comparative, randomized, 1-year study of obese men with mild hypertension. J Hypertens 1991; 9: 431-439.
45. Prisant LM, Carr AA. Antihypertensive drug therapy and insulin resistance. (Editorial) Am J Hypertens 1992; 5: 775-777.
46. Davis BR et al. Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. Hypertension 1992; 19: 393-399.
47. Jarrott B, Conway EL, Maccarrone C, Lewis SJ. Clonidine: understanding its disposition, sites and mechanisms of action. Clin Exp Pharmacol Physiol 1987; 14: 471-479.
48. Campese VM et al. Role of sympathetic nerve inhibition and body sodium-volume state in the antihypertensive action of clonidine in essential hypertension. Kidney International 1980; 18: 351-357.
49. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.
50. Kiowski W et al. Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension 1983; 5: 170-174.
51. Loutzenhiser RD, Epstein M. Calcium antagonists and the kidney. Am J Hypertens 1989; 2 (6 Part 2): S154- S1561.
52. Aristizabal D, Messerli FH, Frohlich ED. Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension. Am J Cardiol 1994; 73: 483-487.
53. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993; 76: 1464-1469.
54. Tuck ML, Bravo EL, Krakoff LR, Friedman CP. Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. Modern Approach to the Treatment of Hypertension Study Group. Am J Hypertens 1990; 3 (12 Part 2): S333-S341.
55. Frohlich ED. Obesity hypertension. Converting enzyme inhibitors and calcium antagonists. Hypertension 1992; 19 (Suppl 1): S119-S123.
56. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59: A59-A65.
57. Messerli FH, Kaesser UR, Losem CJ. Effects of antihypertensive therapy on hypertensive heart disease. Circulation 1989; 80 (Suppl IV): IV145-IV150.
58. Andronico G et al. Nifedipine vs enalapril in treatment of hypertensive patients with glucose intolerance. J Cardiovasc Pharmacol 1991; 18 (Suppl 10): S52-S54.
59. Reaven GM et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8: 461-466.
60. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-188.